The decrease in intracellular polyamines, as a result of treatment with α‐difluoromethylornithine (DFMO), an inhibitor of ODC 25, confers protection against β‐adrenergic‐mediated cardiac hypertrophy 18, 20, 26. This evidence concerns the gene ODC1 and cardiac hypertrophy.